Open AccessDolutegravir and elvitegravir plasma concentrations following cessation of drug intake
Author(s) -
Emilie R Elliot,
Alieu Amara,
Akil Jackson,
Graeme Moyle,
Laura Else,
Saye Khoo,
David Back,
Andrew Owen,
Marta Boffito
Publication year - 2015
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkv425
Subject(s) - elvitegravir , dolutegravir , cobicistat , pharmacokinetics , medicine , pharmacology , dosing , virology , human immunodeficiency virus (hiv) , viral load , antiretroviral therapy
To evaluate dolutegravir and elvitegravir/cobicistat pharmacokinetics in HIV-negative volunteers up to 10 days after drug cessation.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom